118 related articles for article (PubMed ID: 20145638)
41. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
[TBL] [Abstract][Full Text] [Related]
42. c-kit mutational analysis in paraffin material.
Sotlar K
Methods Mol Biol; 2013; 999():59-78. PubMed ID: 23666690
[TBL] [Abstract][Full Text] [Related]
43. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
44. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis.
Kristensen T; Vestergaard H; Bindslev-Jensen C; Møller MB; Broesby-Olsen S;
Am J Hematol; 2014 May; 89(5):493-8. PubMed ID: 24443360
[TBL] [Abstract][Full Text] [Related]
45. All subunits of the interleukin-2 receptor are expressed by canine cutaneous mast cell tumours.
Meyer A; Gruber AD; Klopfleisch R
J Comp Pathol; 2013 Jul; 149(1):19-29. PubMed ID: 23276382
[TBL] [Abstract][Full Text] [Related]
46. Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis.
Hartmann K; Artuc M; Baldus SE; Zirbes TK; Hermes B; Thiele J; Mekori YA; Henz BM
Am J Pathol; 2003 Sep; 163(3):819-26. PubMed ID: 12937123
[TBL] [Abstract][Full Text] [Related]
47. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
[TBL] [Abstract][Full Text] [Related]
48. Aggressive systemic mastocytosis after germ cell tumor of the ovary: C-KIT mutation documentation in both disease states.
Lee JW; Yang WS; Chung SY; Kang JH; Cho B; Kim HK; Kim KM; Jeong DC
J Pediatr Hematol Oncol; 2007 Jun; 29(6):412-5. PubMed ID: 17551405
[TBL] [Abstract][Full Text] [Related]
49. Recognizing mastocytosis in patients with anaphylaxis: value of KIT D816V mutation analysis of peripheral blood.
Broesby-Olsen S; Oropeza AR; Bindslev-Jensen C; Vestergaard H; Møller MB; Siebenhaar F; Kristensen T; Mortz CG; ;
J Allergy Clin Immunol; 2015 Jan; 135(1):262-4. PubMed ID: 25091436
[No Abstract] [Full Text] [Related]
50. The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients.
Won D; Chi HS; Shim H; Jang S; Park CJ; Lee JH
Leuk Res; 2013 Aug; 37(8):883-8. PubMed ID: 23683787
[TBL] [Abstract][Full Text] [Related]
51. Clonality and molecular pathogenesis of mastocytosis.
Akin C
Acta Haematol; 2005; 114(1):61-9. PubMed ID: 15995326
[TBL] [Abstract][Full Text] [Related]
52. Adult-onset systemic mastocytosis in monozygotic twins with KIT D816V and JAK2 V617F mutations.
Broesby-Olsen S; Kristensen TK; Møller MB; Bindslev-Jensen C; Vestergaard H;
J Allergy Clin Immunol; 2012 Sep; 130(3):806-8. PubMed ID: 22608575
[No Abstract] [Full Text] [Related]
53. [Mastocytosis or piebaldism--the KIT mutation decides].
Roupe G
Lakartidningen; 2004 Mar; 101(11):1008-9. PubMed ID: 15055122
[No Abstract] [Full Text] [Related]
54. Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation.
Zappulla JP; Dubreuil P; Desbois S; Létard S; Hamouda NB; Daëron M; Delsol G; Arock M; Liblau RS
J Exp Med; 2005 Dec; 202(12):1635-41. PubMed ID: 16352739
[TBL] [Abstract][Full Text] [Related]
55. Neonatal onset diffuse cutaneous mastocytosis: a case report and review of the literature.
Koga H; Kokubo T; Akaishi M; Iida K; Korematsu S
Pediatr Dermatol; 2011; 28(5):542-6. PubMed ID: 20678092
[TBL] [Abstract][Full Text] [Related]
56. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.
Akin C
J Mol Diagn; 2006 Sep; 8(4):412-9. PubMed ID: 16931579
[TBL] [Abstract][Full Text] [Related]
57. Cutaneous mastocytosis associated with a mixed germ cell tumour of the ovary: report of a case and review of the literature.
Miyagawa S; Hirota S; Park YD; Yamasaki M; Daikoku N; Morikawa H; Yoshioka A; Kitamura Y; Ichijima K
Br J Dermatol; 2001 Aug; 145(2):309-12. PubMed ID: 11531799
[TBL] [Abstract][Full Text] [Related]
58. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
59. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
[TBL] [Abstract][Full Text] [Related]
60. KIT and mastocytosis.
Lim KH; Pardanani A; Tefferi A
Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
